




EGYPTIAN ACADEMIC JOURNAL OF
BIOLOGICAL SCIENCES
MICROBIOLOGY

G



ISSN
2090-0872

WWW.EAJBS.EG.NET

Vol. 15 No. 1 (2023)



Genetic Dissimilarity Adrenoceptor Alpha (ERa) in Hepatitis C virus-induced Cirrhosis and HCC

Mahmoud Amer¹, Alaa Elmetwalli^{2, *}, Attia A. Attia¹, Ayman Hassan³ and Mohamed A. Nasr Eldin¹

1. Botany and Microbiology Department, Faculty of Science, Benha University, Benha, Egypt.
2. Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
3. Department of Medical Research and Diagnostic Labs, Egyptian Liver Research Institute and Hospital, Mansoura, Egypt

*E.Mail: alaa.elmetwalli@outlook.com

ARTICLE INFO

Article History
Received:16/12/2022
Accepted:15/2/2023
Available:20/2/2023

Keywords:

Hepatocellular carcinoma (HCC),

ABSTRACT

Hepatocellular carcinoma (HCC), the fifth most common kind of cancer in the world, is a significant public health concern in Egypt. The development of HCC has been linked to genetic diversity, making the disease challenging to treat. The bulk of the chronic liver illnesses that 95% of HCC patients suffer started by viruses. HCC is a complicated condition. One of the origins of HCC is the hepatitis C virus (HCV). Though being branded to piece a part in a variety of biological courses and having evidence portentously together a carcinogenic and a preemptive influence on the liver, the importance of ERa in the expansion of HCC remains doubtful. It has been shown that those with HCV have a high level of ERa expression. This study reveals how ERa and its variants affect how hepatocarcinogenesis develops.

INTRODUCTION

One of the organs that sex hormones have an impact on is the liver. In animals, a range of liver processes over and above sexual organs like the breast are regulated by sex hormones (Shen and Shi, 2015). In the livers of both sexes, there are high-affinity, low-capacity oestrogen receptors and androgen receptors. There is a mark from many bases signifying gender hormones and their receptors play a part in the development of liver cancer (Wang *et al.*, 2006). In addition, the male sex was also connected to the dissimilarity ER. Plainly, the ESR dissimilarity was first pragmatic in human chief HCC tissues by Villa et al (Villa *et al.*, 1995). (vER). Recently, research by Iavarone et al. connected vER- to the liver ailment (Iavarone *et al.*, 2003). Surprisingly, it endured publicized that HCV-infected individuals had high levels of ER expression. This research displays that the advance of hepatocarcinogenesis and the male preponderance of HCC, on top of convinced viral infections, are prejudiced by ERs and their dissimilarity (Ma *et al.*, 2014). While HCC makes up about 30–40% of all human enmities in Egypt (Ozakyol, 2017), little is understood nearby the AR and ER expression outlines in Egyptian HCC patients.

It was noted that HCV-infected individuals have high levels of ER expression. This research shows that ERs and their dissimilarities are allied to the development of hepatocarcinogenesis, the male predominance of HCC, and several viral contagions (Ma *et al.*, 2014). Consider the fact that HCC resembles 30–40% of all human cancers in Egypt (Ozakyol, 2017), little is known regarding the expression profiles of AR and ERs in Egyptian HCC patients.

The actions of oestrogen are mediated via androgen receptor alpha (ERa) and androgen receptor beta (ERb), which are part of a family of nuclear receptors that control gene expression (Nilsson and Gustafsson, 2002). ERa and ERb are made by two separate genes, ESR1 and ESR2, which are located on different chromosomes (Kyriakidis and Papaioannidou, 2016). Studies have publicized that different ER subtypes participate in signal transduction and have different functions at dissimilar stages of liver disease. The various and ambiguous functions of ER subtypes, chiefly the ERb, in hepatic ailments have long been the focus of research. The mainstream of estrogen's biological paraphernalia in the liver is known to be mediated by ERa (Shi *et al.*, 2014). The ERa has dissimilar isoforms and expressions depending on whether the tissue is healthy, cirrhotic, or has HCC. It's important to mention that ER- was shown to be highly articulated in HCV-infected individuals. This study divulges that ERs and their dissimilarities are linked to both the male predominance of HCC and certain viral infections, over and above the onset of hepatocarcinogenesis (Ma *et al.*, 2014), (Ozakyol, 2017).

Human malignancies have more than twenty dissimilar ERa isoforms. ERa46 and ERa36 are primarily studied. The ERa46 isoform seems to be allied to cell cycle arrest in the G0/G1 phase and a switch to E2-driven growth during cell hyper confluency. Quite a lot of cell cycle regulators seem to be inhibited by it as well. ERa36 seems to be

connected to an upsurge in cell proliferation over activating MAPK-ERK. While their functional reputation is yet unknown, at least five ERb isoforms have been discovered in human tissue. Among the isoforms, ERb2 is a well-researched isoform. Its function seems to be allied to the inhibition of ERa. The authors postulate that ERa degradation by ERb2 results in decreased recruitment of ERa to estrogen-responsive promoters, which suppress genes that control ERa (Srinivasan, 2009).

MATERIALS AND METHODS

Cirrhotic patient with HCC risk and that had high liver stiffness values (17.5 KPa) was further analysed for detection and confirm the HCC polymorphism. Four patients with cirrhosis, cirrhosis with mild HCC (maximum diameter 2.5 cm), and cirrhosis complicated by probable HCC were combined for the third aim (i.e. indeterminate lesions). This latter sample of patients with suspected HCC was then divided into 2 additional cohorts of individuals with ambiguous lesions based on the final diagnosis. The most significant sample that resembled cirrhosis and HCC was further assessed by NGS.

Identification of NG sequence Variants:

The polymorphism discovery technique was cast off to synchronously identify sequence dissimilarities. For variant calling, reads with duplicate markings, more than seven base mismatches, more than three distinct gaps, or MQ more than 30 were disqualified. It was decided that 0.01 would be the anticipated mutation rate or pairwise nucleotide diversity.

RESULTS

Variants, Main Review Remarks:

Table (1) contains a list of variations together with the key review data. To find the same variation in each table, use the gene and c.variant information. Nevertheless, Quality Score per Base Position; Median and Percentiles of Quality Scores are seen at a Certain Read Position. X: base position; Y: PHRED quality score were disclosed in Figure 1; Nucleotide content per base

position; X: base position; Y: number of nucleotides observed per type normalized to the total number of nucleotides at that position

were shown in Figure 2. The Quality scores of UMI reads per base position were revealed in Figure 3.

Table 1: lists variants with the secondary review information.

Gene	c. variant	Impact	Repeat	Count	F Count	R Count	Qual	Region	Chr
ALK	c.4587C>G	mis-sense	No	530	338	192	200	29416366	2
ALK	c.4472A>G	mis-sense	No	841	355	486	200	29416481	2
ALK	c.4381A>G	mis-sense	No	1,088	178	910	200	29416572	2
ALK	c.4338C>T		No	855	290	565	200	29416615	2
ALK	c.4203T>C		No	196	189	7	200	29416750	2
ALK	c.3036G>A		No	712	441	271	200	29449819	2
ALK	c.2535T>C		No	709	379	330	200	29455267	2
ALK	c.702T>A		No	161	136	25	200	29940529	2
ALK	c.27C>G		No	344	340	4	200	30143499	2
PIK3CA	c.-76-14537C>G		No	547	318	229	200	178902001	3
FGFR3	c.882T>C		No	405	234	171	200	1803704	4
FGFR3	c.1953G>A		No	807	456	351	200	1807894	4
PDGFRA	c.1701A>G		No	612	363	249	200	55141055	4
PDGFRA	c.2472C>T		No	312	106	206	200	55152040	4
ESR1	c.1369+13777T>G		No	311	232	79	200	152396036	6
EGFR	c.474C>T		No	807	494	313	200	55214348	7
EGFR	c.2361G>A		No	218	149	69	200	55249063	7
BRAF	c.1929A>G		No	447	274	173	200	140449150	7
NOTCH1	c.5094C>T		No	350	148	202	200	139397707	9
ERBB2	c.3508C>G	mis-sense	No	550	376	174	200	37884037	17




Fig. 1: Quality score per base position.




Fig. 2: Nucleotide content per base position.




Fig. 3: Quality scores of UMI reads per base position.

DISCUSSION

With millions of CHC patients worldwide suffering from cirrhosis, HCV continues to pose a significant public health burden despite the availability of new, extremely effective medications (Vo Quang *et al.*, 2021). Clinically, it is crucial to distinguish between cirrhosis and mild disease because even after the virus has been eradicated, these individuals need to be regularly monitored for consequences like

HCC and should get therapy as soon as possible to avoid the development of decompensated disease (Ibáñez-Samaniego *et al.*, 2022). Due to the invasiveness of the gold standard liver biopsy, the scarcity of highly trustworthy non-invasive biomarkers, and the scarcity of technologies that noninvasively stage fibrosis, disease staging in CHC continues to be a severe difficulty in normal patient care (Múzes *et al.*, 2022). Several diseases, including HCC, have been examined

concerning miRNAs and their potential use as circulating biomarkers. While several possible miRNAs have been discovered so far, no ideal candidate or diagnostic panel has been established (Canale *et al.*, 2018).

To fully comprehend this dissimilarity, further study is required on the various polymorphisms in the ER1 and ER2 genes over and above their connection to a raised-up jeopardy of emerging HCC. HCC has a significant influence on global health since it is the second largest cause of cancer death and the fifth most frequent malignancy in the globe. The fourth-deadliest tumour in Egypt is HCC. Research that may help us understand how HCC acts and its contributing elements, over and above genetic susceptibility to HCC, is thus very interesting and relevant.

This method of analysing polymorphisms may be made simpler if polymorphisms connected to receptor isoforms are found. It might then be improved into a prognosis tool that influences behavioural adjustments in those with higher inherited risks. If our theory is proven correct via scientific research, it may pave the way for the identification of markers that serve as extrapolative aspects for this condition over and above newfangled tactics for creating anticancer drugs based on ER receptor antagonists and improving current therapies.

Conclusion

Overall, our validation research has shown that one or more SNPs in the ER1 gene may be associated with a higher risk of developing and having a more severe case of HCC, over and above a better response to therapy. If our theory is supported by research, new methods for developing anticancer drugs over and above prognostic indicators for HCC may be discovered.

REFERENCES

- Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, and Passardi A (2018): Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. *Critical Reviews in Oncology/Hematology*; 129: 44–53.
- Iavarone M, Lampertico P, Seletti C, Francesca Donato M, Ronchi G, Del Ninno E, & Colombo M (2003): The clinical and pathogenetic significance of estrogen receptor- β expression in chronic liver diseases and liver carcinoma. *Cancer: Interdisciplinary International Journal of the American Cancer Society*; 98(3): 529–534.
- Ibáñez-Samaniego L, Rapado-Castro M, Cabrero L, Navarrete C, García-Mulas S, Ahumada A, and Bañares R (2022): Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study. *European Journal of Neurology*; 29(2): 400–412.
- Kyriakidis I, & Papaioannidou P (2016): Estrogen receptor beta and ovarian cancer: a key to pathogenesis and response to therapy. *Archives of Gynecology and Obstetrics*; 293(6): 1161–1168.
- Ma W-L, Lai H-C, Yeh S, Cai X, & Chang C (2014): Androgen receptor roles in hepatocellular carcinoma, cirrhosis, and hepatitis. *Endocrine-Related Cancer*; 21(3): R165.
- Múzes G, Bohusné Barta B, Szabó O, Horgas V, & Sipos F (2022): Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors. *Biomedicines*; 10(11): 2853.
- Nilsson S, & Gustafsson J-A (2002): Estrogen receptor action. *Critical ReviewsTM in Eukaryotic Gene Expression*; 12(4) 25–33.
- Ozakyol A (2017): Global epidemiology of hepatocellular carcinoma (HCC epidemiology). *Journal of Gastrointestinal Cancer*; 48(3): 238–240.
- Shen M, & Shi H (2015): Sex hormones and their receptors regulate liver energy homeostasis. *International Journal*

- of Endocrinology*; 2(6): 15–23.
- Shi L, Feng Y, Lin H, Ma R, & Cai X (2014): Role of estrogen in hepatocellular carcinoma: is inflammation the key? *Journal of Translational Medicine*; 12(1): 1–9.
- Srinivasan S (2009): Role of E6-AP in steroid hormone receptor-dependent transcription and cellular function; *University of Miami*, 16(12): 235–256.
- Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, and Manenti F (1995): Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. *Cancer Research*; 55(3): 498–500.
- Vo Quang E, Shimakawa Y, & Nahon P (2021): Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. *Liver International*; 41(5): 915–927.
- Wang AG, Lee KY, Kim SY, Choi JY, Lee KH, Kim WH, and Yeom Y Il (2006): The expression of estrogen receptors in hepatocellular carcinoma in Korean patients. *Yonsei Medical Journal*; 47(6): 811–816.